NVS
Novartis AGPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVS
this stock
Novartis AG
|
$287.74B | +12.7% | — | — | 0.3% |
|
LLY
ELI LILLY & Co
|
$1.09T | +7.8% | +44.7% | 41.1 | 1.0% |
|
JNJ
Johnson & Johnson
|
$594.63B | +20.0% | +6.0% | 28.6 | 1.1% |
|
ABBV
AbbVie Inc.
|
$430.71B | +7.7% | +8.6% | 120.1 | 1.2% |
|
MRK
Merck & Co., Inc.
|
$304.81B | +19.2% | +1.4% | 34.8 | 1.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVS | -2.8% | -0.7% | +7.1% | -3.8% | +12.7% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -4.1% | -0.5% | -3.1% | -4.9% | +2.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.